81% rise in Victoza sales drives Novo Nordisk earnings

Article Date: 27/04/2012 10:33
81% rise in Victoza sales drives Novo Nordisk earnings

Vacancy Search

Quick job search

Advanced Search

Latest News

Upcoming events: US decision time for Pozen and data for Merrimack’s lead asset

Welcome to your weekly digest of approaching regulatory and clinical readouts. The US FDA is due to decide on April 25 on Pozen’s so called “safer aspirins”, PA32540 and PA8140, which have...

BioAlliance moves on Topotarget before key US decision

The all-share move that will see France’s BioAlliance buy Denmark’s Topotarget appears to represent a logical combination of two small, oncology-focused drug developers in search of critical...

NHS England to fund hepatitis C drug Sovaldi

NHS England to fund hepatitis C drug Sovaldi

UK industry/MHRA generics quality forum launches

UK industry/MHRA generics quality forum launches

EMA warns about falsifed Herceptin

EMA warns about falsifed Herceptin

MHRA business plan: new products, services, income streams

MHRA business plan: new products, services, income streams

France's BioAlliance merges with Topotarget of Denmark

France's BioAlliance merges with Topotarget of Denmark

Sanofi launches £50,000 UK patient group fund

Sanofi launches £50,000 UK patient group fund

'Financial crisis' for NHS next year, warns King's Fund

'Financial crisis' for NHS next year, warns King's Fund

Sales of cancer drugs soar once again at Roche

Sales of cancer drugs soar once again at Roche
more news